RGD Reference Report - Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson's disease. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson's disease.

Authors: Rosa, Alexandra I  Fonseca, Inês  Nunes, Maria João  Moreira, Sara  Rodrigues, Elsa  Carvalho, Andreia Neves  Rodrigues, Cecília M P  Gama, Maria João  Castro-Caldas, Margarida 
Citation: Rosa AI, etal., Biochim Biophys Acta. 2017 Sep;1863(9):2171-2181. doi: 10.1016/j.bbadis.2017.06.004. Epub 2017 Jun 3.
RGD ID: 13432563
Pubmed: PMID:28583715   (View Abstract at PubMed)
DOI: DOI:10.1016/j.bbadis.2017.06.004   (Journal Full-text)

Impaired mitochondrial function and generation of reactive oxygen species are deeply implicated in Parkinson's disease progression. Indeed, mutations in genes that affect mitochondrial function account for most of the familial cases of the disease, and post mortem studies in sporadic PD patients brains revealed increased signs of oxidative stress. Moreover, exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a mitochondrial complex I inhibitor, leads to clinical symptoms similar to sporadic PD. The bile acid tauroursodeoxycholic acid (TUDCA) is an anti-apoptotic molecule shown to protect against MPTP-induced neurodegeneration in mice, but the mechanisms involved are still incompletely identified. Herein we used MPTP-treated mice, as well as primary cultures of mice cortical neurons and SH-SY5Y cells treated with MPP(+) to investigate the modulation of mitochondrial dysfunction by TUDCA in PD models. We show that TUDCA exerts its neuroprotective role in a parkin-dependent manner. Overall, our results point to the pharmacological up-regulation of mitochondrial turnover by TUDCA as a novel neuroprotective mechanism of this molecule, and contribute to the validation of TUDCA clinical application in PD.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Parkinson's disease treatmentISOPrkn (Mus musculus)13432563; 13432563 RGD 
Parkinson's disease treatmentIDA 13432563 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Prkn  (parkin RBR E3 ubiquitin protein ligase)

Genes (Mus musculus)
Prkn  (parkin RBR E3 ubiquitin protein ligase)

Genes (Homo sapiens)
PRKN  (parkin RBR E3 ubiquitin protein ligase)


Additional Information